Sonu Abraham, MD, FACC

735 posts

Sonu Abraham, MD, FACC banner
Sonu Abraham, MD, FACC

Sonu Abraham, MD, FACC

@SonuAbrahamMD

HF Cardiologist @GillKentucky via @NMCardioVasc, @LaheyHospital, @svhmedres @CalicutCollege | @CircAHA #SoMeEditor | Infiltrative CMs | #HCM | Cardiogenic Shock

Katılım Temmuz 2019
1.7K Takip Edilen1.8K Takipçiler
Sonu Abraham, MD, FACC retweetledi
Women in Heart Transplantation and MCS
Women in Heart Transplantation and MCS@Womenintxp_mcs·
Proud to highlight impactful work by our members led by @rooparao265 @SonuAbrahamMD tackling a critical and timely challenge in #AdvancedHeartFailure and #HeartTransplant care. @NutritionHF @MrudulaMunagala @docbhardwaj @Jcontreras75 @shelleyhallmd #IndraneeRajapreyar @JCardFail
Journal of Cardiac Failure@JCardFail

OHT using HCV NAT+ donors is rising 📈, but management varies widely across 🇺🇸 centers. This national survey shows differences in: ⏱️Timing of Direct-acting-antivirals (DAA) therapy 💊Choice of regimens 📆Duration Read more 🧵

English
0
1
3
917
Sonu Abraham, MD, FACC retweetledi
Journal of Cardiac Failure
Journal of Cardiac Failure@JCardFail·
OHT using HCV NAT+ donors is rising 📈, but management varies widely across 🇺🇸 centers. This national survey shows differences in: ⏱️Timing of Direct-acting-antivirals (DAA) therapy 💊Choice of regimens 📆Duration Read more 🧵
Journal of Cardiac Failure tweet media
English
2
5
11
1.3K
Sonu Abraham, MD, FACC
Sonu Abraham, MD, FACC@SonuAbrahamMD·
4/ Clinical perspective 💡 Coramitug may complement stabilizers & silencers by clearing amyloid deposits. 💡 Biomarker & echo gains suggest cardiac remodeling potential. 💡 Favorable safety supports phase 3 evaluation
→ Moving from disease stabilization to possible reversal
English
0
2
3
1.6K
Sonu Abraham, MD, FACC
Sonu Abraham, MD, FACC@SonuAbrahamMD·
3/ Key findings  ✅ NT-proBNP ↓48% with coramitug 60 mg/kg vs placebo (95% CI −65%, −22%; p=0.0017)  ✅ Improved echo parameters → indicating possible amyloid clearance  ✅ Well tolerated  ⚠️ 6MWT: no significant difference vs placebo  #SoMeEditor @CircAHA
Sonu Abraham, MD, FACC tweet mediaSonu Abraham, MD, FACC tweet media
English
1
2
3
1.9K
Sonu Abraham, MD, FACC
Sonu Abraham, MD, FACC@SonuAbrahamMD·
🧵1/ Current ATTR amyloidosis therapies:   💡 TTR stabilizers   💡 RNA silencers   → Slow new amyloid formation but don’t remove deposits.  Coramitug, a mAb to misfolded TTR, aims to clear amyloid. Phase 2 RCT shows benefits. #AHA25 #SimPub @CircAHA 👇  tinyurl.com/Coramitug
English
1
11
16
3K
Sonu Abraham, MD, FACC
Sonu Abraham, MD, FACC@SonuAbrahamMD·
4/ 💡 Clinical Implications In HT pts: Alirocumab = safe & powerful LDL-C lowering  Short-term plaque impact unclear  Possible reasons: low baseline LDL, inflammation-driven CAV, potent statins used Longer follow-up may be required #SoMeEditor @CircAHA
English
0
3
1
1.3K
Sonu Abraham, MD, FACC
Sonu Abraham, MD, FACC@SonuAbrahamMD·
3/ Key Findings LDL-C dropped: 73 → 32 mg/dL 💪 Total cholesterol, ApoB, Lp(a) ↓ No significant effect on: plaque volume, coronary physiology  Well-tolerated ✅
Sonu Abraham, MD, FACC tweet mediaSonu Abraham, MD, FACC tweet media
English
1
3
1
1.5K
Sonu Abraham, MD, FACC
Sonu Abraham, MD, FACC@SonuAbrahamMD·
It was a pleasure moderating an excellent collection of digital posters at #AHA25 on Hopping Heart Failure Science !
Sonu Abraham, MD, FACC tweet mediaSonu Abraham, MD, FACC tweet mediaSonu Abraham, MD, FACC tweet mediaSonu Abraham, MD, FACC tweet media
English
1
3
15
1K

Keşfet

@rooparao265 @NutritionHF @MrudulaMunagala @docbhardwaj @Jcontreras75 @shelleyhallmd @JCardFail @CircAHA